Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 91, Issue 5, Pages 771-773Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2012.39
Keywords
-
Categories
Funding
- NCRR NIH HHS [KL2RR024132, KL2 RR024132] Funding Source: Medline
- NIA NIH HHS [R01AG025152, R01 AG025152, RC1AG035751, RC1 AG035751] Funding Source: Medline
- NICHD NIH HHS [T32-HD069047, U54HD071598, U10HD063094, T32 HD069047, U54 HD071598, U10 HD063094] Funding Source: Medline
- NIDDK NIH HHS [R01 DK102694] Funding Source: Medline
- NIGMS NIH HHS [T32-GM08425, T32 GM008425] Funding Source: Medline
Ask authors/readers for more resources
Drug-drug interactions (DDIs) are an important clinical and public health concern. Although DDI screening now occurs during drug development, it is difficult to predict clinical importance based on in vitro experiments. Furthermore, older drugs that were not screened may have interactions that have not yet been identified. In this Commentary, we review the importance of DDIs and argue that a translational research approach is needed to produce clinically actionable information as well as generalizable biological knowledge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available